Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Sarepta Therapeutics Inc (NASDAQ:SRPT)

Delayed Data
As of May 04
 -0.80 / -4.44%
Today’s Change
Today|||52-Week Range
What Caused Sarepta Therapeutics To Crash 29% in April
May 03 / MotleyFool.com
Sarepta Can Win Speedy FDA Drug Approval
Apr 28 / TheStreet.com
Stock Market News for May 03, 2016
May 03 / Zacks.com
Biotech Stock Roundup: Biogen Tops on Q1 Earnings, Sarepta, Catalyst Plunge on Regula...
Apr 27 / Zacks.com
Better Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta
May 02 / MotleyFool.com
Despite Pleas, FDA Panel Shuns Drug
Apr 27 / MotleyFool.com
Here???s Why Sarepta Therapeutics (SRPT) Stock is Surging Today
May 02 / Zacks.com
Is This The Last Straw For Sarepta Therapeutics (SRPT) Stock?
Apr 26 / Zacks.com
Jim Cramer -- Following Nelson Peltz Can Make You a Ton of Money
May 02 / TheStreet.com
Why Sarepta Therapeutics, Allegheny Technologies, and Capital Product Partners Slumpe...
Apr 26 / MotleyFool.com
Sarepta Therapeutics (SRPT) Strong On High Relative Volume Today
May 02 / TheStreet.com
Why Sarepta Therapeutics' Stock Is Crashing Today
Apr 26 / MotleyFool.com
Will Sarepta Therapeutics (SRPT) Stock Be Hurt by Jefferies Downgrade?
Apr 29 / TheStreet.com
Why Sarepta Therapeutics Inc. Is Bouncing Back Today
Apr 22 / MotleyFool.com
Why Sarepta Therapeutics Inc. Is Up Big Today
Apr 28 / MotleyFool.com
Why Las Vegas Sands, Sarepta Therapeutics, and United Continental Holdings Slumped To...
Apr 21 / MotleyFool.com
Jim Cramer -- Will FDA Approve Sarepta's Duchenne Drug After All?
Apr 28 / TheStreet.com
Why Is Sarepta Therapeutics (SRPT) Stock Plunging Today?
Apr 21 / Zacks.com
The Zacks Analyst Blog Highlights: Biogen, Sarepta, Catalyst Pharmaceuticals, AbbVie ...
Apr 28 / Zacks.com
Down 41%: Is Sarepta Therapeutics Worth the Risk?
Apr 21 / MotleyFool.com
Trade-Ideas: Sarepta Therapeutics (SRPT) Is Today's Pre-Market Leader Stock
Apr 28 / TheStreet.com